Table 1 Demographic and baseline characteristics of the study population

GA (weeks)

39.9 [39.4–40.3]

30.8 [24.9–33.4]

< 0.001

Birthweight (grams)

3180 [3050–3690]

810 [700–2050]

< 0.001

SGA

1 (9.1)

3 (16.7)

1.000

Female

6 (54.6)

6 (33.3)

0.438

PH diagnosis (postnatal days)

1 (1–1)

6 (2–19)

0.001

Associated conditions

 PPHN

3 (27.3)

4 (22.2)

1.000

 Congenital DH

8 (72.7)

3 (16.7)

0.005

 Severe BPD

0 (0)

10 (62.5)

0.001

At the time of treprostinil administration

 Start day (postnatal day)

4 [2–13]

18.5 [7–54]

0.012

 Weight (gm)

3180 [3080–3510]

1190 [530–2620]

0.021

 Respiratory support

  Mode of ventilation

0.202

   Conventional vent

1 (9.1)

6 (33.3)

   HFOV

10 (90.9)

12 (66.7)

  FiO₂

0.8 [0.6–0.8]

0.8 [0.7–0.95]

0.224

  MAP (cmH₂O)

14 [11–15]

13.5 [12–16]

0.957

  RSS

10.4 [7.2–12]

11.1 [8.4–13.6]

0.499

  iNO (ppm)

50 [40–60]

55 [40–80]

0.843

  PH drug other than iNO

3 (27.3)

11 (61.1)

0.128

 EchoCG

  PAP/sBP

1 [0.78–1.38]

0.79 [0.62–1.03]

0.134

  R to L or bidirectional shunt

4 (36.4)

6 (33.3)

1.000

  Interventricular septal deviation

10 (90.9)

15 (83.3)

1.000

  Ejection fraction (%)

70 [56.3–82.7]

72.4 [58.4–79.5]

0.792